EA201290051A1 - Кристаллическая форма i соли розувастатина цинка - Google Patents

Кристаллическая форма i соли розувастатина цинка

Info

Publication number
EA201290051A1
EA201290051A1 EA201290051A EA201290051A EA201290051A1 EA 201290051 A1 EA201290051 A1 EA 201290051A1 EA 201290051 A EA201290051 A EA 201290051A EA 201290051 A EA201290051 A EA 201290051A EA 201290051 A1 EA201290051 A1 EA 201290051A1
Authority
EA
Eurasian Patent Office
Prior art keywords
zinc
salt
rosuvastatina
crystal form
dyslipidemia
Prior art date
Application number
EA201290051A
Other languages
English (en)
Other versions
EA020944B1 (ru
Inventor
Ференц Барта
Дьёрдь Кованьине Лакс
Балаж Волк
Йожеф Баркоци
Дьёрдь Моровьян
Дьёрдь Краснаи
Кальман Надь
Дьюла Шимиг
Дьёрдь Ружич
Дьёрдь Клементис
Имре Капуи
Петер Шлегель
Адриенн Кестейи
Жужанна Сент-Кирайи
Валерия Хофманне Фекете
Янош Имре
Original Assignee
Эгиш Дьёдьсердьяр Ньильваношан Мюкеде Ресвеньтаршашаг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эгиш Дьёдьсердьяр Ньильваношан Мюкеде Ресвеньтаршашаг filed Critical Эгиш Дьёдьсердьяр Ньильваношан Мюкеде Ресвеньтаршашаг
Publication of EA201290051A1 publication Critical patent/EA201290051A1/ru
Publication of EA020944B1 publication Critical patent/EA020944B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к кристаллической форме I соли розувастатина цинка (2:1), способу ее получения и ее применению в качестве фармацевтически активного ингредиента для лечения заболеваний, связанных с метаболизмом липидов, включающих гиперлипопротеинемию, гиперхолестеринемию, дислипидемию и атеросклероз.
EA201290051A 2009-07-24 2009-07-24 Кристаллическая форма i соли розувастатина цинка EA020944B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/HU2009/000064 WO2011010174A1 (en) 2009-07-24 2009-07-24 Crystalline form i rosuvastatin zinc salt

Publications (2)

Publication Number Publication Date
EA201290051A1 true EA201290051A1 (ru) 2012-09-28
EA020944B1 EA020944B1 (ru) 2015-02-27

Family

ID=41258771

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290051A EA020944B1 (ru) 2009-07-24 2009-07-24 Кристаллическая форма i соли розувастатина цинка

Country Status (11)

Country Link
US (1) US9023838B2 (ru)
EP (1) EP2483248B1 (ru)
JP (1) JP5702778B2 (ru)
CN (1) CN102548971B (ru)
AU (1) AU2009350099B2 (ru)
EA (1) EA020944B1 (ru)
ES (1) ES2598162T3 (ru)
HU (1) HUE029858T2 (ru)
IL (1) IL217898A0 (ru)
UA (1) UA103544C2 (ru)
WO (1) WO2011010174A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230737B1 (hu) * 2010-11-16 2018-01-29 EGIS Gyógyszergyár Nyrt Eljárás rosuvastatin só előállítására
HU231036B1 (hu) * 2013-09-30 2019-12-30 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Koleszterin bioszintézis gátló hatóanyagot és koleszterin abszorpciót gátló hatóanyagot tartalmazó kombinációs gyógyszerkészítmény

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ552389A (en) * 2004-08-06 2009-05-31 Transform Pharmaceuticals Inc Statin pharmaceutical compositions and related methods of treatment
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
EP2066644A2 (en) * 2006-08-04 2009-06-10 Glenmark Pharmaceuticals Limited Salts of rosuvastatin and processes for their preparation
HU230637B1 (hu) * 2007-10-12 2017-05-29 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Eljárás rosuvastatin intermedierek előállítására
HU230981B1 (hu) * 2007-10-12 2019-08-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Eljárás rosuvastatin só előállítására
AU2010205464A1 (en) * 2009-01-15 2011-08-18 Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag Process for the preparation of rosuvastatin salts

Also Published As

Publication number Publication date
WO2011010174A8 (en) 2012-07-05
JP5702778B2 (ja) 2015-04-15
EP2483248A1 (en) 2012-08-08
HUE029858T2 (en) 2017-04-28
EP2483248B1 (en) 2016-07-20
EA020944B1 (ru) 2015-02-27
JP2013500250A (ja) 2013-01-07
CN102548971A (zh) 2012-07-04
WO2011010174A1 (en) 2011-01-27
US9023838B2 (en) 2015-05-05
CN102548971B (zh) 2015-09-16
ES2598162T3 (es) 2017-01-25
AU2009350099B2 (en) 2015-10-29
UA103544C2 (ru) 2013-10-25
US20120178729A1 (en) 2012-07-12
IL217898A0 (en) 2012-03-29
AU2009350099A1 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
MY177742A (en) Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
AU2016204216A1 (en) Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
EA201291220A1 (ru) Производные аминопиримидина в качестве модуляторов lrrk2
EA201591390A1 (ru) Пиразол[1,5-a]пиримидины для противовирусного лечения
EA202091303A3 (ru) Композиция ингибитора jak для местного применения
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201200763A1 (ru) Замещенные производные карбамоилметиламиноуксусной кислоты в качестве новых ингибиторов nep
EA201390723A1 (ru) Аминозамещенные производные бисфенилпентановой кислоты в качестве ингибиторов nep
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
MX348606B (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2).
RS53617B1 (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
MX341482B (es) Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23.
MX338088B (es) Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf).
EA201390984A1 (ru) Гетероциклические соединения, подходящие для лечения дислипидемии
MX2021010046A (es) Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas.
IN2012DN02502A (ru)
EA201390771A1 (ru) Способ получения фармацевтических промежуточных соединений высокой чистоты
MX343165B (es) Agonistas del receptor 5-ht4 para el tratamiento de demencia.
EA201290051A1 (ru) Кристаллическая форма i соли розувастатина цинка
NZ611072A (en) Method for preparing rosuvastatin salts
EA201591487A1 (ru) Производные замещенной бисфенилбутановой кислоты в качестве ингибиторов nep с улучшенной in vivo эффективностью
HU1000616D0 (en) Crystalline pharmaceutically active ingredient

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ MD RU